Current Opinion in Organ Transplantation器官移植新见
Current Opinion in Organ Transplantation(英文缩写 CURR OPIN ORGAN TRAN),ISSN 1087-2418,eISSN 1531-7013,中文译名:器官移植新见 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-28 至 2026-09-28，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 2.269 | Q3 |
| 2022 | 2.200 | Q3 |
| 2023 | 1.800 | Q3 |
| 2024 | 1.900 | Q3 |
| 2025 | 2.500 | Q2 |
Current Opinion in Organ Transplantation 最新收录文献
-
1. Immunosuppression in vascularized composite allotransplantation.
PMID:日期:2026-10-01Vascularized composite allotransplantation (VCA) restores form and function after disfiguring tissue loss with the required need for lifelong immunosuppression for a non-life-saving indication, creating a distinct risk-benefit ratio compared to other solid organ transplants. This review summarizes recent advances in VCA immunosuppression, with emphasis on strategies that reduce drug-related toxicity while preserving graft function. Long-term cohort data continue to document substantial nephrotoxic, metabolic, infectious, and oncologic morbidity from tacrolimus-based triple therapy, with measurable decline in renal function within the first posttransplant year and tacrolimus exposure as the strongest correlate. Costimulation blockade has produced preclinical and early clinical efficacy, particularly belatacept combined with antithymocyte globulin induction to avoid the need for long-term use of calcineurin inhibitors. Next-generation anti-CD40 agents are positioned to overcome the thromboembolic toxicity that limited earlier anti-CD154 antibodies. Regulatory T-cell therapy and chimerism-based tolerance remain promising and investigational. Tacrolimus-based triple therapy remains the clinical standard, with its concomitant nephrotoxicity requiring kidney transplantation after face and hand transplantation in some cases. Costimulation blockade-based, calcineurin inhibitor-sparing protocols represent an advanced path toward safer VCA immunosuppression.
-
2. Gut microbiota and complications in kidney transplantation: a balancing act between commensal and pathogenic bacteria.
PMID:日期:2026-10-01Recent work has linked gut dysbiosis, an imbalance of commensal and pathogenic bacteria, to complications in kidney transplant recipients. The purpose of this review is to evaluate the gut microbiota's relationship to important complications in kidney transplantation. In both allogeneic hematopoietic stem cell transplant and solid organ transplant recipients, gut dysbiosis has been linked to an increased risk of infections and higher mortality rates. In kidney transplant recipients, elevated intestinal uropathogen abundance is associated with development of urinary tract infection, and an imbalance between commensal and pathogenic bacteria has been linked to posttransplant diarrhea. Gut dysbiosis with elevated abundance of pathogenic bacteria and decreased abundance of commensal bacteria is associated with urinary tract infections and posttransplant diarrhea in kidney transplantation.
-
3. Pain syndromes in transplantation: the role of the gut microbiome.
PMID:日期:2026-10-01The purpose of this review is to discuss common pain phenotypes in transplantation, summarize known gut microbiome features associated with chronic pain, and to map known gut microbiome features in transplantation with diagnosis-independent pain features. Persistent pain is common across solid organ and hematopoietic stem cell transplantation, arises from diverse mechanisms, and often extends well beyond the perioperative period. Growing evidence supports the gut microbiome as a biologically plausible modulator of chronic pain across disease states, including transplantation. Alterations in microbial diversity, microbial metabolites, intestinal barrier integrity, and neuroimmune signaling have been linked to pain amplification and central sensitization across multiple chronic pain conditions. In transplant populations, exposure to immunosuppressive therapies, antibiotics, metabolic comorbidities, and other transplant-related stressors creates a unique environment for sustained microbiome disruption that may contribute to persistent symptom burden. Collectively, these data highlight the importance to systematically assess and manage pain as a core transplant outcome rather than a secondary concern, and to highlight the potential role of the gut microbiome as a risk screening tool or a therapeutic target for pain interventions. Although mechanistic and observational data support biologic plausibility, transplant-specific microbiome-pain evidence remains preliminary and warrants longitudinal investigation.
-
4. Gut microbiota and acute rejection in solid organ transplantation.
PMID:日期:2026-10-01The microbiota can modulate immune responses. Associations between dysbiosis and acute allograft rejection have been observed in clinical transplantation and investigated mechanistically in animal models. Recent advances will be reviewed. Reductions in gut microbial diversity, as well as loss of short-chain fatty acid (SCFA)-producing taxa have been reported to precede diagnosis of acute rejection in solid organ transplant patients, and these signatures can sometimes be found even before transplantation. Experimental models have identified the ability of certain bacterial strains or of oral supplementation with SCFA to prolong graft survival. Conversely, serum accumulation of the bacterial-derived metabolite lysophosphatidic acid (LPA) has been associated with rejection. Microbial and metabolic changes may alter either the priming phase or the effector phase of the alloimmune response. Dysbiosis can precede acute rejection and some strains and metabolites appear protective while others may be detrimental to the graft. The ability for microbial taxa or communities, or their derived metabolites, to affect different immune phases of the alloresponse suggests that combining therapeutic targeting of these microbial axes may have additive or synergistic effects.
-
5. Gut microbiota links to infection in liver transplantation.
PMID:日期:2026-10-01Infectious complications remain a major source of morbidity and mortality following liver transplantation, with Enterococcus spp. and Enterobacterales among the most common causative pathogens. Increasing evidence suggests that the intestinal microbiota plays a central role in regulating susceptibility to these infections through maintenance of colonization resistance, epithelial barrier integrity, and host immune signaling. Patients with end-stage liver disease frequently develop intestinal dysbiosis characterized by reduced microbial diversity, depletion of obligate anaerobes, and expansion of pathobionts prior to transplantation. Liver transplantation further exacerbates these disruptions through perioperative antibiotics, surgical injury, ischemia-reperfusion injury, altered bile acid metabolism, and immunosuppressive therapy. Recent studies have demonstrated associations between loss of microbial diversity, depletion of beneficial microbial metabolites, including short-chain fatty acids and secondary bile acids, and subsequent postoperative infections in liver transplant recipients. These findings suggest that the microbiome may function both as a mechanistic mediator and biomarker of infection risk. Mechanisms of colonization resistance, microbiome-mediated maintenance of the intestinal barrier, and the emergence of pathobiont domination, are critical in the development of infection following liver transplant and requires strategies to diagnose and therapeutically restore microbiome function to avoid infection.
-
6. Gut dysbiosis and multidrug-resistant colonization in solid organ transplantation.
PMID:日期:2026-10-01The purpose of this review is to summarize recent advances in the understanding of the interplay between gut dysbiosis and MDRO colonization and infection in SOT patients. Recent studies have added complementary metagenomics, internal transcribed spacer sequencing, metabolomics, and pathway analysis to descriptive microbiome profiling. Enhanced ecologic frameworks have identified microbial, functional, and clinical signatures associated with MDRO colonization and infection. Microbiome-targeting interventions are emerging as strategies to reduce morbidity associated with MDRO infection. MDRO infection is a significant cause of post-transplant mortality. Persistent gut dysbiosis peri-transplant reduces colonization resistance and predisposes patients to adverse clinical outcomes. Understanding the dynamics of this process will aid in the care of these high-risk patients.
-
7. Precision medicine guided development of new immunosuppression strategies in solid organ transplantation.
PMID:日期:2026-10-01Corticosteroids, calcineurin inhibitors, antimetabolites, and mammalian target of rapamycin (mTOR) inhibitors have formed the basis of immunosuppression in clinical solid organ transplantation for decades. This review aims to outline recent advances in precision-based immunosuppression for solid organ transplantation. Co-stimulation blockade has been explored as both tolerogenic and maintenance immunosuppression over the last two decades, resulting in the application of belatacept in clinical settings. Dual co-stimulation blockade is the latest in this area of study. Recent updates in monoclonal antibody-based immunotherapy have resulted in widespread off-label clinical implementation of eculizumab and alemtuzumab with new drugs still in phase II/II trials. Additional strategies, including autologous regulatory T cell (Treg) and chimeric antigen receptor-Treg cell (CAR-Treg) based therapies, are at the forefront of therapeutic immunomodulation. Early data have demonstrated safety and feasibility with ongoing phase II studies in these cell-based therapies, aiming to verify efficacy in early and long-term graft survival. The past decade has seen advancement in costimulatory blockade, as well as immune modulatory therapy with monoclonal antibodies. Cellular therapies such as CAR-Tregs remain in the early clinical trial phase.
-
8. Update on costimulatory blockade in transplantation: a review of recent literature.
PMID:日期:2026-10-01Calcineurin inhibitors (CNIs) and steroids remain the major components of immunosuppressive regimens despite long-term side effects including nephrotoxicity and derangements in metabolic parameters. Belatacept, the first costimulatory blockade molecule approved for prophylaxis of kidney transplant rejection, has been shown to improve renal function over long-term use compared with CNIs, though concerns regarding increased rates of acute rejection has limited its widespread use. This update describes the initial development of belatacept and costimulation blockade; reviews the current state of its use as a clinically applicable immunosuppressant; and discusses the future direction of costimulation blockade and its use with newly emerging immunosuppressive strategies. Iterative refinements to belatacept-containing protocols have reduced the incidence of acute rejection to rates comparable to those seen in CNI-based regimens, while preserving both a glomerular filtration rate advantage as well as improvements in long-term patient and graft survival. Increasingly sophisticated mechanistic understanding of immunology has allowed belatacept to be combined with newly developed, targeted therapies to expand its use. Transplant of organs other than kidney have begun to use belatacept with encouraging results. Belatacept offers significant advantages in kidney transplantation, minimizing the negative effects of steroids and CNIs. New combinations with standard and emerging medications, along with new indications and clinical applications, continues to widen its use and allow increasing access.
-
9. GWAS studies and polygenic risk scores in organ transplantation.
PMID:日期:2026-09-28To summarize recent developments published between 1 January 2024 and 15 August 2026 in genome-wide and polygenic analyses of solid organ transplantation, with a focus on kidney, heart, liver, and lung transplantation. Recent studies demonstrate that posttransplant phenotypes can reflect distinct genetic contributions from the recipient, donor organ, and donor-recipient pair. Donor and recipient polygenic risk scores have been associated with graft function, graft survival, and posttransplant complications, although their incremental predictive value beyond clinical factors has generally been modest. Genome-wide analyses of donor-recipient mismatch have identified genetic differences outside the HLA region associated with rejection and graft loss. Emerging evidence suggests that the biological relevance of mismatch depends not only on the extent of genetic difference, but also on its functional nature and direction. However, most studies remain limited by small, highly selected cohorts, limited independent replication, and predominant European ancestry. Genome-wide and polygenic approaches are expanding the conceptual framework of transplant genetics beyond individual variants and HLA matching. Current evidence provides stronger support for biological relevance than clinical utility. Larger, diverse, and deeply phenotyped donor-recipient cohorts are needed to determine whether genome-wide genetic measures can improve posttransplant risk prediction and donor-recipient matching.
-
10. Management of patients with cardiopulmonary comorbidities awaiting liver transplantation.
PMID:日期:2026-09-28The need for liver transplant continues to rise especially among those with metabolic dysfunction associated steatotic liver disease. Consequently, more transplant candidates have concurrent cardiopulmonary comorbidities. This review summarizes contemporary developments in cardiopulmonary care in liver transplant candidates. Recent guidelines recommend noninvasive anatomic cardiovascular assessment before invasive coronary angiography for evaluation of coronary artery disease. Post-PCI DAPT can be used for as short as 1 month before waitlist activation. Practice-based guidance recommends echocardiographic surveillance on the waitlist especially with the evolving data on the impact of Cirrhotic Cardiomyopathy. Emerging evidence suggests that guideline directed medical therapy for heart disease is safe in patients with advanced liver disease. Updated portopulmonary hypertension guidelines emphasize revised screening and diagnostic thresholds, early initiation of medical therapy, and timely liver transplant evaluation. Management of cardiopulmonary comorbidities in liver transplant candidates continues to advance yet remains nuanced requiring a multidisciplinary approach for optimal care.